Bexarotene: A promising anticancer agent

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 2, 2010, Pages 201-205

  Qu, Liyan ^a   Tang, Xiuwen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Bexarotene; Cell cycle; Differentiation; Multidrug resistance

Indexed keywords

BEXAROTENE;

ADULT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ASTHENIA; CANCER PREVENTION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DRUG APPROVAL; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; METASTASIS; MULTIDRUG RESISTANCE; NAUSEA; PRIORITY JOURNAL; SHORT SURVEY; SKIN TOXICITY;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES;

EID: 71349084776     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1140-4     Document Type: Short Survey

References (65)

1. K Niederreither V Subbarayan P Dolle P Chambon 1999 Embryonic retinoic acid synthesis is essential for early mouse post-implantation development Nat Genet 21 346 347 10.1038/7788 (Pubitemid 29159586)
2. R Lotan 1996 Retinoids in cancer prevention FASEB 10 1031 1039
3. A Fanjul MI Dawson PD Hobbs, et al. 1994 A new class of retinoids with selective inhibition of AP-1 inhibits proliferation Nature 372 107 111 10.1038/372107a0 7969403
4. P Fenaux C Chomienne L Degos 2001 All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia Semin Hematol 38 1 13 25 10.1016/S0037-1963(01)90002-2 11172536
5. MF Boehm L Zhang BA Badea, et al. 1994 Synthesis and structureactivity relationships of novel retinoid X receptor-selective retinoids J Med Chem 37 2930 2941 10.1021/jm00044a014 8071941
6. KH Dragnev JR Rigas E Dmitrovsky 2000 The retinoids and cancer prevention mechanisms Oncologist 5 361 368 10.1634/theoncologist.5-5-361 11040271
7. RM Niles 2000 Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer Nutrition 16 1084 1089 10.1016/S0899-9007(00) 00436-6 11118831
8. S Toma P Raffo L Isnardi, et al. 1999 Retinoids in lung cancer chemoprevention and treatment Ann Oncol 10 95 102 10.1023/A:1008385128190
9. SF Wong 2001 Oral bexarotene in the treatment of cutaneous T-cell lymphoma Ann Pharmacother 35 1056 1065 10.1345/aph.10223 11573857
10. RC Yocum VA Miller RP Warrell, et al. 2001 Long-term followup of patients with advanced non-small cell lung cancer treated with oral bexarotene Proc Am Soc Clin Oncol 20 267
11. BS Mann JR Johnson MH Cohen R Justice R Pazdur 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247 1252 10.1634/theoncologist.12-10-1247 17962618 (Pubitemid 350106355)
12. GR Blumenschein Jr FR Khuri J von Pawel, et al. 2008 Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II J Clin Oncol 26 1879 1885 10.1200/JCO.2007.12.2689 18398153
13. P Tooker WC Yen SC Ng, et al. 2007 Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification Cancer Res 67 4425 4433 10.1158/0008-5472.CAN-06-4495 17483357 (Pubitemid 46815092)
14. PH Brown K Subbaramaiah AP Salmon, et al. 2008 Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid Cancer Prev Res (Phila Pa) 1 208 214
15. S Zanardi D Serrano A Argusti, et al. 2006 Clinical trials with retinoids for breast cancer chemoprevention Endocr Relat Cancer 13 51 68 10.1677/erc.1.00938 16601279
16. RA Abbott SJ Whittaker SL Morris, et al. 2009 Bexarotene therapy for mycosis fungoides and Sézary syndrome Br J Dermatol 160 1299 1307 10.1111/j.1365-2133.2009.09037.x 19222457
17. SR Lessin EA Ross H Wu 2008 Treatment of parapsoriasis with bexarotene 1% gel Int J Dermatol 47 1325 1327 10.1111/j.1365-4632.2008.03740.x 19126035
18. D Breneman P Sheth V Berger, et al. 2007 Phase II clinical trial of bexarotene gel 1% in psoriasis J Drugs Dermatol 6 501 506 17679184
19. AY Bedikian C Plager N Papadopoulos, et al. 2000 A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma Oncol Rep 7 883 886 10854563
20. DE Tsai SM Luger C Andreadis, et al. 2008 A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia Clin Cancer Res 14 5619 5625 10.1158/1078-0432.CCR-07-5185 18765556
21. WL Read MQ Baggstrom PM Fracasso R Govindan 2008 A phase I study of bexarotene and rosiglitazone in patients with refractory cancers Chemotherapy 54 236 241 10.1159/000140468 18560232 (Pubitemid 351929276)
22. KH Dragnev WJ Petty S Shah, et al. 2005 Bexarotene and erlotinib for aerodigestive tract cancer J Clin Oncol 23 8757 8764 10.1200/JCO.2005.01.9521 16314636 (Pubitemid 46211521)
23. JM Hanifin V Stevens P Sheth D Breneman 2004 Novel treatment of chronic severe hand dermatitis with bexarotene gel Br J Dermatol 150 545 553 10.1046/j.1365-2133.2003.05729.x 15030340 (Pubitemid 38446312)
24. Talpur R, Vu J, Bassett R, Stevens V, Duvic M (2009) Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009 Aug 12. [Epub ahead of print]
25. YY Liu MP Stokkel AM Pereira, et al. 2006 Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma Eur J Endocrinol 154 525 531 10.1530/eje.1.02123 16556714
26. RA Krathen S Ward M Duvic 2003 Bexarotene is a new treatment option for lymphomatoid papulosis Dermatology 206 142 147 10.1159/000068451 12592082 (Pubitemid 36205282)
27. M Duvic K Hymes P Heald, et al. 2001 Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2456 2471 11331325 (Pubitemid 32391217)
28. M Duvic AG Martin Y Kim, et al. 2001 Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 581 593 11346336 (Pubitemid 32458440)
29. AP Kannangara D Levitan AB Fleischer Jr 2009 Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma J Dermatolog Treat 20 169 176 10.1080/09546630802562427 19016373
30. E Papadavid C Antoniou V Nikolaou, et al. 2008 Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides Am J Clin Dermatol 9 169 173 10.2165/00128071-200809030-00005 18429646 (Pubitemid 351572059)
31. R Ramlau P Zatloukal J Jassem, et al. 2008 Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I J Clin Oncol 26 1886 1892 10.1200/JCO.2007.12.2614 18398154
32. JR Rigas KH Dragnev 2005 Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene Oncologist 10 22 33 10.1634/theoncologist.10-1- 22 15632250 (Pubitemid 40171249)
33. N Rizvi MJ Hawkins PD Eisenberg, et al. 2001 Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer Clin Lung Cancer 2 210 215 10.3816/CLC.2001.n.005 14700480
34. FJ Esteva J Glaspy S Baidas, et al. 2003 Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer J Clin Oncol 21 999 1006 10.1200/JCO.2003.05.068 12637463 (Pubitemid 46594127)
35. C D'Acunto C Gurioli I Neri 2009 Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB J Dermatolog Treat 1 1 4 10.1080/09546630903103980
36. F Foss MF Demierre G DiVenuti 2005 A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 106 454 457 10.1182/blood-2004-11-4570 15811959 (Pubitemid 40981237)
37. WC Yen WW Lamph 2006 A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer Prostate 66 305 316 10.1002/pros.20347 16245282 (Pubitemid 43191230)
38. M Steinhoff M Beyer J Roewert-Huber, et al. 2008 Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate J Am Acad Dermatol 58 S88 S91 10.1016/j.jaad.2007.07. 012 18489056
39. ML Lokitz HK Wong 2007 Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides Photodermatol Photoimmunol Photomed 23 255 257 10.1111/j.1600-0781.2007.00315.x 17986063 (Pubitemid 350055615)
40. L Altucci A Rossin O Hirsch, et al. 2005 Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor Cancer Res 65 8754 8765 10.1158/0008-5472.CAN-04-3569 16204045 (Pubitemid 41377364)
41. DJ Straus M Duvic T Kuzel, et al. 2007 Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma Cancer 109 1799 1803 10.1002/cncr.22596 17366595 (Pubitemid 46668543)
42. Q Feng D Sekula Y Guo, et al. 2008 UBE1L causes lung cancer growth suppression by targeting cyclin D1 Mol Cancer Ther 7 3780 3788 10.1158/1535-7163.MCT-08-0753 19074853
43. J Langenfeld H Kiyokawa D Sekula, et al. 1997 Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism Proc Natl Acad Sci USA 94 12070 12074 10.1073/pnas.94.22.12070 9342364 (Pubitemid 27467844)
44. N Nieto-Rementería G Pérez-Yarza MD Boyano, et al. 2008 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma Br J Dermatol 25 519 526
45. KH Dragnev WJ Petty SJ Shah, et al. 2007 A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer Clin Cancer Res 13 1794 1800 10.1158/1078-0432.CCR-06-1836 17363535 (Pubitemid 46952948)
46. IP Uray Q Shen HS Seo, et al. 2009 Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1 J Biol Chem 284 1 345 353 10.1074/jbc.M804721200 18957410
47. PJ Reddig RL Juliano 2005 Clinging to life: cell to matrix adhesion and cell survival Cancer Metastasis Rev 24 425 439 10.1007/s10555-005-5134-3 16258730 (Pubitemid 41569982)
48. SX Ying S Seal N Abbassi, et al. 2007 Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines Leuk Lymphoma 48 1003 1014 10.1080/10428190701242358 17487744 (Pubitemid 47161572)
49. I Tamm Y Wang E Sausville, et al. 1998 IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, Caspases, and anticancer drugs Cancer Res 58 5315 5320 9850056
50. C Zhang P Hazarika X Ni, et al. 2002 Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action Clin Cancer Res 8 1234 1240 12006543
51. FS Alyaqoub Y Liu L Tao, et al. 2008 Modulation by bexarotene of mRNA expression of genes in mouse lung tumors Mol Carcinog 47 165 171 10.1002/mc.20383 17849452
52. RM Cesario J Stone WC Yen RP Bissonnette WW Lamph 2006 Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer Cancer Lett 240 225 233 10.1016/j.canlet.2005.09.010 16271436 (Pubitemid 44093823)
53. M Kizaki MI Dawson R Heyman, et al. 1996 Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro Blood 87 1977 1984 8634447
54. MT Kuo 2009 Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities Antioxid Redox Signal 11 99 133 10.1089/ars.2008.2095 18699730
55. F Thiebaut T Tsuruo H Hamada, et al. 1987 Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci 84 7735 7738 10.1073/pnas.84.21.7735 2444983
56. K Wu Y Zhang XC Xu, et al. 2002 The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice Cancer Res 62 6376 6380 12438218
57. WC Yen WW Lamph 2005 The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma Mol Cancer Ther 4 824 834 10.1158/1535-7163.MCT-05-0018 15897247 (Pubitemid 40767127)
58. WC Yen MR Corpuz RY Prudente, et al. 2004 A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer Clin Cancer Res 10 8656 8664 10.1158/1078-0432.CCR-04-0979 15623650 (Pubitemid 40053434)
59. WC Yen RY Prudente WW Lamph 2004 Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma Breast Cancer Res Treat 88 141 148 10.1007/s10549-004- 1426-5 15564797 (Pubitemid 39575571)
60. DR Jones RM Broad LD Comeau, et al. 2002 Inhibition of nuclear factor kappaB chemosensitizes non-small-cell lung cancer through cytochrome c release and caspase activation J Thorac Cardiovasc Surg 123 310 317 10.1067/mtc.2002. 118684 11828291 (Pubitemid 34127119)
61. M Bentires-Alj V Barbu M Fillet, et al. 2003 NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells Oncogene 22 90 97 10.1038/sj.onc.1206056 12527911 (Pubitemid 36152887)
62. MG García LD Alaniz RI Cordo Russo, et al. 2009 PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines Leuk Res 33 288 296 10.1016/j.leukres.2008.06.010 18640717
63. Y Nakajima R Madhyastha M Maruyama 2009 2-Deoxy-d-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression Anticancer Agents Med Chem 9 239 245 19199868
64. R Kumar IJ Fidler 1998 Angiogenic molecules and cancer metastasis In Vivo 12 27 34 9575423
65. WC Yen RY Prudente MR Corpuz, et al. 2006 A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours Br J Cancer 94 654 660 16495926